{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-425243","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2026-10-19T20:11:18+00:00","discovered_at":"2026-10-19T20:12:01.267484+00:00","generated_at":"2026-10-19T20:12:06.824402+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CRISPR Therapeutics promotes Andrew Silver to CFO as Raju Prasad resigns","bullets":["Andrew J. Silver, 42, was promoted to Chief Financial Officer effective October 19, 2026; he will serve as principal financial and accounting officer.","Silver's annual salary is $515,000 with a 45% target bonus and a one-time grant of 25,000 restricted stock units vesting on the second anniversary.","Raju Prasad, Ph.D. resigned as CFO to pursue external opportunities; CRISPR said the resignation was not due to any disagreement and he is expected to stay until on or before November 30, 2026.","The employment agreement provides six months' notice for involuntary departure, or 12 months plus equity acceleration within 12 months after a Change in Control."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-425243","json":"https://secwatch.observer/filing/0001193125-26-425243.json","markdown":"https://secwatch.observer/filing/0001193125-26-425243.md","text":"https://secwatch.observer/filing/0001193125-26-425243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/0001193125-26-425243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/crsp-20261019.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-19T20:12:06.824402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cede9ff463","claim":"Andrew J. Silver changed role as Chief Financial Officer at CRISPR Therapeutics AG.","evidence_excerpt":"On October 19, 2026, CRISPR Therapeutics AG (the “Company”) announced the promotion of Andrew J. Silver, currently the Company’s SVP, Finance, to be the Company’s Chief Financial Officer effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/0001193125-26-425243-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}